AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 818
- Registration Number
- NCT04305496
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT04305405
- Locations
- 🇯🇵
Research Site, Zentsuji-shi, Japan
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04293172
Open-label Extension Study of Brazikumab in Ulcerative Colitis
Phase 2
Terminated
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 57
- Registration Number
- NCT04277546
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 217
- Registration Number
- NCT04272463
- Locations
- 🇮🇹
Research Site, Verona, Italy
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
Phase 3
Active, not recruiting
- Conditions
- Endometrial Neoplasms
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 813
- Registration Number
- NCT04269200
- Locations
- 🇪🇸
Research Site, Mallorca, Spain
A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD2373 subcutaneous injectionDrug: Placebo
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT04269031
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
Phase 1
Completed
- Conditions
- Healthy Volunteers (Intended Indication: Chronic Kidney Disease)
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT04256629
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT04249362
- Locations
- 🇪🇸
Research Site, Sabadell(Barcelona), Spain
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Phase 2
Withdrawn
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04239014
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
© Copyright 2025. All Rights Reserved by MedPath